Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 29, 2002

View Archived Issues

Company Profile: Entomed

U.S. launch of Paremyd scheduled for March

Aricept associated with significant benefits in the treatment of vascular dementia

Forest receives approvable letter for Lexapro in major depressive disorder

Iressa under regulatory review in two major markets for NSCLC

Phase IIb results reported for OvaRex in metastatic ovarian cancer

Argenta Discovery and Lundbeck collaborate on CNS program

Synt:em collaborates with Baxter to develop monoclonal antibody mimetics

Novirio research consortium receives grant for antiflavivirus drug candidate development

Schering AG and Mologen to develop cell-based therapies

First Plantibodies candidate heads for clinical testing

Chemokine CCR1 receptor antagonist effective in mouse model of renal fibrosis

Preparation and use of new series of PDE5 inhibitors

Acylphenylurea derivatives effective as inhibitors of glycogen phosphorylase according to Aventis

Novel caspase inhibitors identified at Vertex

Pfizer team synthesizes selective adenosine A2A receptor agonists

Benzamide-containing compounds that act as ligands of thyroid hormone receptor beta

Preparation and use of purine derivatives with antiviral activity claimed

Rituximab + CHOP as a new drug combination for aggressive NHL

TKT's Fabry's disease enzyme replacement therapy available for use in E.U.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 28, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 28, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...